Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Our popular solutions

Key benefits:

Direct access to your target Pharma audience
A cohesive marketing campaign
Effective reporting

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Citeline, Biomedtracker, Pharma Consulting, Datamonitor Heal...

COVID-19 24 hour webinar recordings

Catch up on any missed COVID-19 24 hour webinar sessions

Topic Cardiovascular Coronavirus

Full video
Scrip

Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

View article
Generics Bulletin

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Topic Coronavirus Distribution

View article
Generics Bulletin

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Topic Coronavirus

View article
Generics Bulletin

Remdesivir Compulsory Licensing Is A Dead End For Europe

In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.

Topic Coronavirus Intellectual Property Policy & Regulation

View article
Generics Bulletin

Remdesivir Licensing Agreements for Generics Companies

Keep up with crucial developments in the generics industry as Gilead signs non-exclusive, voluntary licensing agreements with several generics manufacturers in an effort to more widely manufacture and distribute the COVID-19 drug remdesivir, used to help patients recover from severe coronavirus infections faster.

Topic Drug Development Landscape

Single report
Awareness, Thought leadership, Scrip

Scrip Asia 100: Sponsorship Opportunities

The annual “Scrip Asia 100”, the highly anticipated financial performance ranking of pharma companies headquartered in the APAC region, is coming soon. Don’t miss your opportunity to position yourself as a leader in APAC pharma with a sponsorship in this indispensable publication.

Topic Company Analysis Market Intelligence Outlook

View article
HBW Insight

Italy's Supplements Market Gets Big Boost From COVID After Solid 2019

Coronavirus pandemic drove up sales of vitamin C supplements and other immunity boosters in Italy in the opening three months of the year.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

No Evidence That Vitamin D Prevents Or Treats COVID-19

UK's NICE reviews whether Vitamin D can prevent or treat COVID-19, finds evidence wanting.

Topic Coronavirus Dietary Supplements

View article
HBW Insight

Nurofen Ad Pulled In NZ For Irresponsible Message During COVID Pandemic

Reckitt Benckiser's TV ad for Nurofen in New Zealand drew numerous complaints for being "socially irresponsible" during the COVID-19 pandemic.

Topic Coronavirus Advertising, Marketing & Sales

View article
HBW Insight

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

Assertions that no convincing evidence supports that probiotics available in the US treat symptoms of diarrhea, irritable bowel syndrome or allergies look at the category as a whole and not individual strains shown to help with specific conditions, say consumer health industry groups.

Topic Coronavirus Dietary Supplements Research & Development

View article
Scrip

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Plus Updates On Mylan, Sinovac, Zydus Cadila

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Operation Warp Speed Spreads Its Bets With 1.6bn Novavax Deal

Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.

Topic Coronavirus Business Strategies

View article
Scrip

2020 Titans Of Pharma Infographic

Scrip’s eagerly awaited annual snapshot of pharma leadership in 2020 is here. The 2020 Titans of Pharma infographic features key information on the industry’s top leaders and the mega companies they oversee.

Topic Leadership Market Access

View infographic